Share Price and Basic Stock Data
Last Updated: December 12, 2025, 8:17 pm
| PEG Ratio | 9.84 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gujarat Inject (Kerala) Ltd operates within the pharmaceuticals sector, a field marked by volatility and rapid changes in consumer demand. The company’s revenue trajectory has been quite erratic over the years. For instance, sales reported in FY 2025 surged to ₹19.05 Cr, a significant leap from the ₹0.17 Cr recorded in FY 2023. This upward move appears promising, especially considering the company’s sales figures of ₹5.79 Cr in FY 2024. However, the company has shown inconsistent quarterly performance, with some quarters like March 2023 and September 2023 recording zero sales, raising questions about sustainability. The operating profit margin (OPM) has been teetering on the edge, shifting from negative figures to a modest 5.34% in FY 2025. Overall, while the recent uptick in revenues could signal a turnaround, potential investors should remain cautious about the company’s historical volatility in sales and profitability.
Profitability and Efficiency Metrics
Turning to profitability, Gujarat Inject has shown some resilience. The net profit for FY 2025 stood at ₹1.02 Cr, a notable improvement from the previous fiscal year where it was just ₹0.04 Cr. This growth is reflected in the earnings per share (EPS), which rose to ₹0.70 from ₹0.09 in FY 2024. However, the price-to-earnings (P/E) ratio of 105 raises concerns about valuation, suggesting that the stock may be perceived as overvalued relative to its earnings. The return on equity (ROE) was reported at 10.15%, which is decent but not extraordinary for the pharmaceuticals sector. Additionally, the company’s cash conversion cycle (CCC) of 137.57 days indicates potential operational inefficiencies, as longer cycles can tie up capital and affect liquidity. Investors should weigh these profitability metrics against the backdrop of fluctuating revenues to gauge the company’s true operational health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Gujarat Inject reveals a mixed picture. The total liabilities have increased significantly to ₹11.95 Cr in FY 2025, while reserves remain negative at ₹-4.62 Cr, indicating that the company has yet to build a solid equity base. Notably, the company carries no long-term debt, which is a positive aspect, suggesting a conservative approach to leverage. The current ratio is notably high at 4.73, indicating a strong liquidity position, which is essential for navigating short-term obligations. However, the price-to-book value ratio of 3.80x suggests that the market is pricing the stock at a premium compared to its book value, which could be a red flag for some investors. Overall, while the absence of debt is a strength, the lack of reserves and high valuation ratios could raise concerns about long-term sustainability and financial health.
Shareholding Pattern and Investor Confidence
Gujarat Inject’s shareholding pattern reflects a fully public ownership structure, with 100% of shares held by the public as of March 2025. This widespread public ownership, which has grown from 6,341 shareholders in December 2022 to 8,151 by September 2025, suggests increasing investor interest. However, the absence of institutional investors—both domestic and foreign—may indicate a lack of confidence from larger, more sophisticated market players. This could be a double-edged sword, as retail-driven stocks can be more volatile yet present opportunities for significant upside if the company continues on its growth trajectory. While the growing shareholder base is a positive sign, the lack of institutional support may lead to greater price fluctuations and risks, which retail investors should consider.
Outlook, Risks, and Final Insight
The outlook for Gujarat Inject hinges on its ability to maintain revenue growth and improve operational efficiency. The recent sales surge could be a turning point, yet the erratic quarterly performance raises concerns about sustainability. Risks include potential operational inefficiencies, as indicated by the lengthy cash conversion cycle, and the high P/E ratio, which may deter value-conscious investors. Furthermore, the company’s negative reserves may pose challenges in financing future growth without incurring debt. Investors should remain vigilant about market conditions and operational performance. In this context, while the stock presents an intriguing opportunity for growth, it also carries significant risks that require careful consideration. As always, a balanced approach that weighs potential rewards against inherent risks will be crucial for making informed investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 237/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,250 Cr. | 390 | 479/192 | 88.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.1 | 31.0/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,476.95 Cr | 1,156.03 | 52.77 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.04 | 0.03 | 0.10 | 0.00 | 0.15 | 0.00 | 0.22 | 5.42 | 3.05 | 8.61 | 3.15 | 4.24 | 2.42 |
| Expenses | 0.03 | 0.39 | 0.10 | 0.02 | 0.11 | 0.00 | 0.25 | 5.37 | 2.88 | 8.07 | 2.87 | 4.15 | 2.32 |
| Operating Profit | 0.01 | -0.36 | 0.00 | -0.02 | 0.04 | 0.00 | -0.03 | 0.05 | 0.17 | 0.54 | 0.28 | 0.09 | 0.10 |
| OPM % | 25.00% | -1,200.00% | 0.00% | 26.67% | -13.64% | 0.92% | 5.57% | 6.27% | 8.89% | 2.12% | 4.13% | ||
| Other Income | 0.00 | 0.40 | 0.00 | 0.03 | 0.00 | 0.02 | 0.04 | 0.00 | 0.00 | 0.17 | 0.00 | 0.01 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 | 0.02 | 0.01 | 0.05 | 0.17 | 0.71 | 0.28 | 0.10 | 0.10 |
| Tax % | 0.00% | 25.00% | 0.00% | 25.00% | 0.00% | 0.00% | 20.00% | 23.53% | 14.08% | 25.00% | 30.00% | 20.00% | |
| Net Profit | 0.01 | 0.03 | 0.00 | 0.01 | 0.03 | 0.01 | 0.00 | 0.04 | 0.12 | 0.61 | 0.21 | 0.07 | 0.07 |
| EPS in Rs | 0.02 | 0.06 | 0.00 | 0.02 | 0.06 | 0.02 | 0.00 | 0.04 | 0.08 | 0.42 | 0.14 | 0.05 | 0.05 |
Last Updated: August 19, 2025, 2:15 pm
Below is a detailed analysis of the quarterly data for Gujarat Inject (Kerala) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.42 Cr.. The value appears to be declining and may need further review. It has decreased from 4.24 Cr. (Mar 2025) to 2.42 Cr., marking a decrease of 1.82 Cr..
- For Expenses, as of Jun 2025, the value is 2.32 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.15 Cr. (Mar 2025) to 2.32 Cr., marking a decrease of 1.83 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.10 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For OPM %, as of Jun 2025, the value is 4.13%. The value appears strong and on an upward trend. It has increased from 2.12% (Mar 2025) to 4.13%, marking an increase of 2.01%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 20.00%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Mar 2025) to 20.00%, marking a decrease of 10.00%.
- For Net Profit, as of Jun 2025, the value is 0.07 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.07 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.05. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 1:00 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.02 | 1.57 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 5.79 | 19.05 | 18.42 |
| Expenses | 0.00 | 0.00 | 0.02 | 1.56 | 0.07 | 0.03 | 0.01 | 0.13 | 0.07 | 0.54 | 5.74 | 17.98 | 17.41 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.01 | -0.07 | -0.03 | -0.01 | -0.12 | -0.05 | -0.37 | 0.05 | 1.07 | 1.01 |
| OPM % | 0.00% | 0.64% | -1,200.00% | -250.00% | -217.65% | 0.86% | 5.62% | 5.48% | |||||
| Other Income | 0.00 | 0.00 | 2.30 | 0.00 | 0.05 | 0.02 | 0.01 | 0.01 | 0.05 | 0.43 | 0.06 | 0.18 | 0.18 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.06 | 0.11 | 1.25 | 1.19 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 18.18% | 19.20% | |||||
| Net Profit | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.04 | 0.08 | 1.02 | 0.96 |
| EPS in Rs | 0.00 | 0.00 | 4.69 | 0.02 | -0.04 | -0.02 | 0.00 | -0.22 | 0.00 | 0.08 | 0.07 | 0.70 | 0.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -99.57% | -300.00% | 50.00% | 100.00% | 100.00% | 100.00% | 1175.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.43% | 350.00% | 50.00% | 0.00% | 0.00% | 1075.00% |
Gujarat Inject (Kerala) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 884% |
| TTM: | 112% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 465% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 47% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 11% |
Last Updated: September 5, 2025, 3:40 pm
Balance Sheet
Last Updated: December 10, 2025, 4:26 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 11.29 | 14.63 | 14.63 |
| Reserves | -7.64 | -7.95 | -5.64 | -5.64 | -5.66 | -5.66 | -5.66 | -5.77 | -5.76 | -5.72 | -2.75 | -4.62 | -4.48 |
| Borrowings | 2.55 | 2.86 | 0.56 | 0.57 | 0.59 | 0.59 | 0.59 | 0.69 | 0.73 | 0.61 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.38 | 0.38 | 0.36 | 0.20 | 0.21 | 0.20 | 0.20 | 0.22 | 0.22 | 0.53 | 0.15 | 1.94 | 1.55 |
| Total Liabilities | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
| Total Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 11.70 |
Below is a detailed analysis of the balance sheet data for Gujarat Inject (Kerala) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.63 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.63 Cr..
- For Reserves, as of Sep 2025, the value is -4.48 Cr.. The value appears to be improving (becoming less negative). It has improved from -4.62 Cr. (Mar 2025) to -4.48 Cr., marking an improvement of 0.14 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.55 Cr.. The value appears to be improving (decreasing). It has decreased from 1.94 Cr. (Mar 2025) to 1.55 Cr., marking a decrease of 0.39 Cr..
- For Total Liabilities, as of Sep 2025, the value is 11.70 Cr.. The value appears to be improving (decreasing). It has decreased from 11.95 Cr. (Mar 2025) to 11.70 Cr., marking a decrease of 0.25 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 11.70 Cr.. The value appears to be declining and may need further review. It has decreased from 11.95 Cr. (Mar 2025) to 11.70 Cr., marking a decrease of 0.25 Cr..
- For Total Assets, as of Sep 2025, the value is 11.70 Cr.. The value appears to be declining and may need further review. It has decreased from 11.95 Cr. (Mar 2025) to 11.70 Cr., marking a decrease of 0.25 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-4.48 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.55 | -2.86 | -0.56 | -0.56 | -0.66 | -0.62 | -0.60 | -0.81 | -0.78 | -0.98 | 0.05 | 1.07 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Working Capital Days | -8,395.00 | -106.94 | -17,520.00 | -9,490.00 | -1,545.88 | 167.06 | 137.76 | |||||
| ROCE % | 2.65% | 13.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.70 | 0.09 | 0.05 | 0.00 | -0.12 |
| Diluted EPS (Rs.) | 0.70 | 0.09 | 0.05 | 0.00 | -0.12 |
| Cash EPS (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Revenue From Operations / Share (Rs.) | 13.01 | 5.13 | 0.35 | 0.04 | 0.02 |
| PBDIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| Net Profit / Share (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| PBDIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBT Margin (%) | 6.58 | 1.81 | 31.93 | 13.05 | -911.24 |
| Net Profit Margin (%) | 5.34 | 1.42 | 23.62 | 9.77 | -911.24 |
| Return on Networth / Equity (%) | 10.15 | 0.96 | -4.90 | -0.25 | 0.00 |
| Return on Capital Employeed (%) | 12.54 | 1.23 | -14.62 | -0.64 | 22.60 |
| Return On Assets (%) | 8.51 | 0.95 | 13.53 | 3.41 | -599.51 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | -0.54 | -0.47 | -0.47 |
| Total Debt / Equity (X) | 0.00 | 0.00 | -0.72 | -0.83 | -0.78 |
| Asset Turnover Ratio (%) | 1.85 | 1.29 | 0.94 | 0.54 | 0.72 |
| Current Ratio (X) | 4.73 | 40.77 | 0.10 | 0.04 | 0.02 |
| Quick Ratio (X) | 4.73 | 40.77 | 0.10 | 0.04 | 0.02 |
| Interest Coverage Ratio (X) | 837.07 | 237.71 | 1108.59 | 144.19 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 679.13 | 187.11 | 820.29 | 108.27 | 0.00 |
| Enterprise Value (Cr.) | 36.07 | 8.32 | 4.38 | 1.48 | 0.00 |
| EV / Net Operating Revenue (X) | 1.89 | 1.44 | 25.18 | 65.66 | 0.00 |
| EV / EBITDA (X) | 28.73 | 78.68 | 78.78 | 499.58 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 1.94 | 22.04 | 33.50 | 0.00 |
| Price / BV (X) | 3.80 | 1.31 | -4.57 | -0.86 | 0.00 |
| Price / Net Operating Revenue (X) | 2.00 | 1.94 | 22.08 | 33.70 | 0.00 |
| EarningsYield | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Gujarat Inject (Kerala) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 5. It has increased from 0.09 (Mar 24) to 0.70, marking an increase of 0.61.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 5. It has increased from 0.09 (Mar 24) to 0.70, marking an increase of 0.61.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 3. It has increased from 0.07 (Mar 24) to 0.69, marking an increase of 0.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.84. It has decreased from 7.57 (Mar 24) to 6.84, marking a decrease of 0.73.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.84. It has decreased from 7.57 (Mar 24) to 6.84, marking a decrease of 0.73.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 13.01. It has increased from 5.13 (Mar 24) to 13.01, marking an increase of 7.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 2. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.85. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.85. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 2. It has increased from 0.07 (Mar 24) to 0.69, marking an increase of 0.62.
- For PBDIT Margin (%), as of Mar 25, the value is 6.59. This value is below the healthy minimum of 10. It has increased from 1.82 (Mar 24) to 6.59, marking an increase of 4.77.
- For PBIT Margin (%), as of Mar 25, the value is 6.59. This value is below the healthy minimum of 10. It has increased from 1.82 (Mar 24) to 6.59, marking an increase of 4.77.
- For PBT Margin (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 10. It has increased from 1.81 (Mar 24) to 6.58, marking an increase of 4.77.
- For Net Profit Margin (%), as of Mar 25, the value is 5.34. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 5.34, marking an increase of 3.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.15. This value is below the healthy minimum of 15. It has increased from 0.96 (Mar 24) to 10.15, marking an increase of 9.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.54. This value is within the healthy range. It has increased from 1.23 (Mar 24) to 12.54, marking an increase of 11.31.
- For Return On Assets (%), as of Mar 25, the value is 8.51. This value is within the healthy range. It has increased from 0.95 (Mar 24) to 8.51, marking an increase of 7.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.85. It has increased from 1.29 (Mar 24) to 1.85, marking an increase of 0.56.
- For Current Ratio (X), as of Mar 25, the value is 4.73. This value exceeds the healthy maximum of 3. It has decreased from 40.77 (Mar 24) to 4.73, marking a decrease of 36.04.
- For Quick Ratio (X), as of Mar 25, the value is 4.73. This value exceeds the healthy maximum of 2. It has decreased from 40.77 (Mar 24) to 4.73, marking a decrease of 36.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 837.07. This value is within the healthy range. It has increased from 237.71 (Mar 24) to 837.07, marking an increase of 599.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 679.13. This value is within the healthy range. It has increased from 187.11 (Mar 24) to 679.13, marking an increase of 492.02.
- For Enterprise Value (Cr.), as of Mar 25, the value is 36.07. It has increased from 8.32 (Mar 24) to 36.07, marking an increase of 27.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 1.89, marking an increase of 0.45.
- For EV / EBITDA (X), as of Mar 25, the value is 28.73. This value exceeds the healthy maximum of 15. It has decreased from 78.68 (Mar 24) to 28.73, marking a decrease of 49.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.00, marking an increase of 0.06.
- For Price / BV (X), as of Mar 25, the value is 3.80. This value exceeds the healthy maximum of 3. It has increased from 1.31 (Mar 24) to 3.80, marking an increase of 2.49.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.00, marking an increase of 0.06.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Inject (Kerala) Ltd:
- Net Profit Margin: 5.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.54% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.15% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 679.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 105 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shop No. 15, K-Tower, Haveli Resi-Cum Plaza, Vadodra Gujarat 390014 | gikl2015@hotmail.com www.gujaratinject.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murli Nair | Chairman & Wholetime Director |
| Ms. Reena Mahatma | Non Executive Director |
| Mr. Rushiraj Zaverbhai Patel | Non Exe. & Ind. Director |
| Mr. Nileshbhai Vinubhai Rangholiya | Non Exe. & Ind. Director |
FAQ
What is the intrinsic value of Gujarat Inject (Kerala) Ltd?
Gujarat Inject (Kerala) Ltd's intrinsic value (as of 13 December 2025) is 65.31 which is 116.98% higher the current market price of 30.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 44.0 Cr. market cap, FY2025-2026 high/low of 31.0/17.0, reserves of ₹-4.48 Cr, and liabilities of 11.70 Cr.
What is the Market Cap of Gujarat Inject (Kerala) Ltd?
The Market Cap of Gujarat Inject (Kerala) Ltd is 44.0 Cr..
What is the current Stock Price of Gujarat Inject (Kerala) Ltd as on 13 December 2025?
The current stock price of Gujarat Inject (Kerala) Ltd as on 13 December 2025 is 30.1.
What is the High / Low of Gujarat Inject (Kerala) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Inject (Kerala) Ltd stocks is 31.0/17.0.
What is the Stock P/E of Gujarat Inject (Kerala) Ltd?
The Stock P/E of Gujarat Inject (Kerala) Ltd is 105.
What is the Book Value of Gujarat Inject (Kerala) Ltd?
The Book Value of Gujarat Inject (Kerala) Ltd is 6.93.
What is the Dividend Yield of Gujarat Inject (Kerala) Ltd?
The Dividend Yield of Gujarat Inject (Kerala) Ltd is 0.00 %.
What is the ROCE of Gujarat Inject (Kerala) Ltd?
The ROCE of Gujarat Inject (Kerala) Ltd is 13.5 %.
What is the ROE of Gujarat Inject (Kerala) Ltd?
The ROE of Gujarat Inject (Kerala) Ltd is 11.0 %.
What is the Face Value of Gujarat Inject (Kerala) Ltd?
The Face Value of Gujarat Inject (Kerala) Ltd is 10.0.